MỐI LIÊN QUAN GIỮA CHÊNH LỆCH eGFR DỰA TRÊN CREATININE VÀ CYSTATIN C VỚI TÌNH TRẠNG THIỂU CƠ Ở BỆNH NHÂN BỆNH THẬN MẠN

Abstract

Background: Sarcopenia is common and associated with poor outcomes in CKD. The difference eGFRdiff = eGFRcys – eGFRcr may indirectly reflect muscle status. This study investigated the association between eGFRdiff and sarcopenia indices in CKD patients. Methods: A cross-sectional study was conducted on 101 patients (CKD stages 1–5). Muscle mass (SMI, ASM) was measured by BIA; muscle strength by handgrip; and physical performance by gait speed. Sarcopenia was defined per AWGS 2019 criteria. Results: Median eGFRdiff was −5.0 mL/min/1.73 m². The eGFRdiff ≥ −5 group had significantly higher ASM and handgrip strength (p < 0.05). In patients with BMI ≥ 23 kg/m², eGFRdiff positively correlated with SMI (r = 0.262; p = 0.043) and handgrip strength (r = 0.273; p = 0.035). Handgrip strength was independently associated with eGFRdiff < -5 (OR = 0.911; p = 0.044; AUC = 0.7028). Conclusion: The difference between creatinine- and cystatin C–based estimated glomerular filtration rates was closely associated with skeletal muscle mass and strength. eGFRdiff is a simple and feasible indirect indicator that may help identify early risk of low muscle mass in clinical practice, particularly in patients with normal or high BMI.